JP2016515800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515800A5 JP2016515800A5 JP2015558997A JP2015558997A JP2016515800A5 JP 2016515800 A5 JP2016515800 A5 JP 2016515800A5 JP 2015558997 A JP2015558997 A JP 2015558997A JP 2015558997 A JP2015558997 A JP 2015558997A JP 2016515800 A5 JP2016515800 A5 JP 2016515800A5
- Authority
- JP
- Japan
- Prior art keywords
- types
- genes
- test
- ccg
- panel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 112
- 230000014509 gene expression Effects 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 51
- 239000000523 sample Substances 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 29
- 238000002512 chemotherapy Methods 0.000 claims description 24
- 238000012408 PCR amplification Methods 0.000 claims description 20
- 238000004393 prognosis Methods 0.000 claims description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 238000010837 poor prognosis Methods 0.000 claims description 14
- 108700039887 Essential Genes Proteins 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000002411 adverse Effects 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 238000004590 computer program Methods 0.000 claims description 4
- 239000012502 diagnostic product Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 238000011226 adjuvant chemotherapy Methods 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767490P | 2013-02-21 | 2013-02-21 | |
| US61/767,490 | 2013-02-21 | ||
| US201361860470P | 2013-07-31 | 2013-07-31 | |
| US61/860,470 | 2013-07-31 | ||
| US201361894733P | 2013-10-23 | 2013-10-23 | |
| US61/894,733 | 2013-10-23 | ||
| PCT/US2014/017706 WO2014130825A1 (en) | 2013-02-21 | 2014-02-21 | Gene signatures for lung cancer prognosis and therapy selection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016515800A JP2016515800A (ja) | 2016-06-02 |
| JP2016515800A5 true JP2016515800A5 (enExample) | 2017-01-26 |
Family
ID=51391852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558997A Pending JP2016515800A (ja) | 2013-02-21 | 2014-02-21 | 肺癌の予後および治療選択のための遺伝子サイン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140315935A1 (enExample) |
| EP (1) | EP2958999A4 (enExample) |
| JP (1) | JP2016515800A (enExample) |
| CA (1) | CA2901761A1 (enExample) |
| WO (1) | WO2014130825A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE212013000295U1 (de) | 2013-05-06 | 2016-02-02 | Hitachi Chemical Co. America, Ltd. | Vorrichtungen zum Einfangen von Zielmolekülen |
| JP6730983B2 (ja) * | 2014-09-19 | 2020-07-29 | ザ プロボスト，フェローズ，ファウンデーション スカラーズ，アンド ジ アザー メンバーズ オブ ボード，オブ ザ カレッジ オブ ザ ホーリー アンド アンディブ．トリニティー オブ クイーン エリザベス，ニアー ダブリン | 癌の再発リスクを予測する方法 |
| WO2016077537A1 (en) * | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
| KR101825369B1 (ko) * | 2015-06-15 | 2018-02-06 | 강원대학교산학협력단 | 암의 예후 판단용 유전자 바이오 마커 및 이의 용도 |
| WO2017040520A1 (en) | 2015-08-31 | 2017-03-09 | Hitachi Chemical Co., Ltd. | Molecular methods for assessing urothelial disease |
| BR112021003095A2 (pt) * | 2018-08-20 | 2021-05-11 | Trustees Of Boston University | métodos relacionados à gravidade e progressão de lesão pré-maligna bronquial |
| CN111187833A (zh) * | 2018-11-14 | 2020-05-22 | 上海生物芯片有限公司 | Plk1和bub1b基因联合作为肺癌生物标志物的用途 |
| CN118782151B (zh) * | 2024-07-24 | 2025-08-29 | 西南医科大学附属医院 | 一种基于“靶点-药物加权积分制”构建脓毒症疾病关键靶点与药物筛选方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6809118B2 (en) * | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
| EP3524697B1 (en) * | 2009-01-07 | 2024-10-02 | Myriad Genetics, Inc. | Cancer biomarkers |
| WO2012030840A2 (en) * | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| CA2845568A1 (en) * | 2011-08-19 | 2013-02-28 | Myriad Genetics, Inc. | Gene signatures for lung cancer prognosis and therapy selection |
-
2014
- 2014-02-21 US US14/186,290 patent/US20140315935A1/en not_active Abandoned
- 2014-02-21 WO PCT/US2014/017706 patent/WO2014130825A1/en not_active Ceased
- 2014-02-21 JP JP2015558997A patent/JP2016515800A/ja active Pending
- 2014-02-21 CA CA2901761A patent/CA2901761A1/en not_active Abandoned
- 2014-02-21 EP EP14754889.5A patent/EP2958999A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515800A5 (enExample) | ||
| Ewing et al. | Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during multiple sclerosis progression | |
| CN103733065B (zh) | 用于癌症的分子诊断试验 | |
| Yuan et al. | Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients | |
| CN103299188B (zh) | 用于癌症的分子诊断试验 | |
| Fumagalli et al. | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology | |
| Yang et al. | Association of polymorphisms in pre-miRNA with inflammatory biomarkers in rheumatoid arthritis in the Chinese Han population | |
| Song et al. | Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients | |
| HK1201583A1 (en) | Paclitaxel response markers for cancer | |
| JP2018505658A5 (enExample) | ||
| AU2012261820A1 (en) | Molecular diagnostic test for cancer | |
| EP2527459A1 (en) | Blood-based gene detection of non-small cell lung cancer | |
| JP2011523549A5 (enExample) | ||
| CN110423816B (zh) | 乳腺癌预后量化评估系统及应用 | |
| Ali et al. | Association analyses of a genetic variant in long non-coding RNA MEG3 with breast cancer susceptibility and serum MEG3 expression level in the Egyptian population | |
| Zurawska et al. | Multiple sclerosis: circRNA profile defined reveals links to B-cell function | |
| Wang et al. | A robust blood gene expression-based prognostic model for castration-resistant prostate cancer | |
| Wang et al. | Liu x | |
| Zou et al. | The serum microRNA profile of intrahepatic cholestasis of pregnancy: identification of novel noninvasive biomarkers | |
| EP2808815A2 (en) | Identification of biologically and clinically essential genes and gene pairs, and methods employing the identified genes and gene pairs | |
| Ma et al. | Integrated analysis from multicentre studies identities m7G-related lncRNA-derived molecular subtypes and risk stratification systems for gastric cancer | |
| Yang et al. | Aging-related biomarkers for the diagnosis of Parkinson’s disease based on bioinformatics analysis and machine learning | |
| Lee et al. | Association between a functional HLA-G 14-bp insertion/deletion polymorphism and susceptibility to autoimmune diseases: a meta-analysis | |
| Dix et al. | Genome-wide expression profiling reveals S100B as biomarker for invasive aspergillosis | |
| Kim et al. | COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype |